


Hot Topics and Trend Drug Development of Hyperlipidemia

Problem - Remained risk of cardiovascular event

The remained risk of cardiovascular event has not been decreased while cholesterol control has been dramatically improved up to the edge of possible range by globally and widely used drugs such as [statin](#), [Ezetimibe](#) and [PCSK9 inhibitor](#).



Significance of TG control

In recent study, it has been remarked significance of triglyceride (TG) control. The new drug development that inhibits regulating factors of LPL activity that is critical for TG metabolism has been progressing on a fast track.

Future Drug Development (Angptl3, ApoC3, Angptl4 and Angptl8 inhibitors)

The factors that negatively regulate LPL activity like [Angptl3](#) inhibitor and recent hot topics “the development of [ApoC3](#) inhibitor” have been actively discussed by researchers. It has been expected that the most focused drug development might be [Angptl4](#) inhibitor and/or [Angptl8](#) inhibitor in near future.

Possible Drug Development Target (ApoA5 and GPIHBP1)

It has been considered that possibly the factors that [positively regulate LPL activity](#) like [ApoA5](#) or [GPIHBP1](#) might be targeted for drug development for the purpose of TG controls. Especially it has been suggested that ApoA5 could be important risk factor for early-onset myocardial infarction as same as LDL receptor by genome analysis.

Lipid Metabolism - Assay Kit

[27264 LPL/HTGL Activity Control Plus Kit - IBL](#)

[27745 Human ANGPTL2 Assay Kit - IBL](#)

[27185 LPL/HTGL Activity Assay Kit - IBL](#)

[27750 Human ANGPTL3 \(h.s.\) Assay Kit - IBL](#)

[27180 Human Serum HTGL Assay Kit - IBL](#)

[27749 Human ANGPTL4 Assay Kit - IBL](#)

[27182 Human EL Full-Length Assay Kit - IBL](#)



[27795 Human ANGPTL8 Assay Kit - IBL](#)

[27263 Human EL C-Terminal Assay Kit - IBL](#)

[27181 Human ApoB-100 Assay Kit - IBL](#)

[27179 Human GPIHBP1 Assay Kit - IBL](#)

[27191 Human ApoA5 Assay Kit - IBL](#)



GPIHBP1 is an essential factor for LPL activity.